Skip to main content
. 2020 May 6;176(1):124–136. doi: 10.1093/toxsci/kfaa049

Figure 7.

Figure 7.

Effects of 7-day pravastatin and cerivastatin application on myobundle morphology and MMP release. A, Representative myobundle cross-sectional images stained for nuclei (DAPI). B, Quantification of nuclei number per myobundle cross-section normalized to drug-free control (n = 200 myotubes from 8 myobundles per group, from N = 2 donors). C, Representative myobundle cross-sectional images stained for filamentous actin (F-actin). D, Quantification of f-actin area per myobundle cross-section normalized to drug-free controls (n = 8 myobundles from N = 2 donors). Cumulative daily release profile and 7-day cumulative quantification of (E, F) MMP-1, (G, H) MMP-2, (I, J) MMP-3 (n = 8 myobundles, n = 2 technical replicates from N = 2 donors). *p < .01 from CTL and #p < .05 from IGF 0.5. CTL, drug-free control; IGF 0.1, 0.1 mg/ml IGF-1; IGF 0.5, 0.5 mg/ml IGF-1; Dex 1, 1 μM dexamethasone; Dex 25, 25 μM dexamethasone.